Fig. 1
Schematic diagram of the mechanism of QR-KLU combined with anti-PD-1 antibody for treating subcutaneous Hepa1–6 liver tumors in mice (drawn using Figdraw). PD-1 programmed cell death receptor-1, QR-KLU peptide (QR)–drug (KLU) conjugate.
Fig. 1 | Scientific Reports
